Long-term follow-up after clot removal for pulmonary embolism
Part of Heart & circulation, Lungs & breathing clinical trials.
This study tracks how patients do long-term after having a clot in the lung treated with a device called the Indigo Aspiration System. It aims to better understand safety and outcomes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have symptoms of a fresh lung blood clot (pulmonary embolism) that started 14 days ago or less
- Your heart strain test is high enough (RV/LV ratio 0.9 or more) on a CT angiogram or ultrasound (echocardiogram)
- Your planned first treatment is the Indigo Aspiration System, done according to its instructions
- You are 18 years or older and can give informed consent
- You do not have reasons you cannot take blood thinners (anticoagulants) at treatment doses
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how people do after an acute pulmonary embolism (a blood clot in the lungs). It aims to understand real-world outcomes over follow-up and may help improve how care teams track patients after treatment.
This study compares different real-world treatments for a serious but stable type of blood clot in the lungs (called intermediate-high risk pulmonary embolism). It aims to see which treatments work best in everyday patients, including those with other health conditions.
This study tests a new device (AlphaVac) that removes blood clots from the lungs using a thin tube inserted through a vein. It may be an option for people with acute pulmonary embolism who have signs of heart strain or low blood pressure.
This trial tests a device that removes blood clots from the lungs in people with a recent pulmonary embolism. It may help improve blood flow and reduce strain on the heart.
This trial tests a device called the FlowTriever to remove blood clots from the lungs in people with a pulmonary embolism that is not too severe. The goal is to see if this treatment can help improve heart function and symptoms without major surgery.
This trial compares three treatments for an intermediate-high risk pulmonary embolism: a minimally invasive clot removal procedure (embolectomy), a low-dose clot-dissolving medication, or standard blood thinning (heparin). The goal is to see which approach works best to prevent worsening while reducing bleeding risks.
Hear when a new Pulmonary Embolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.